RET fusion driven (RETfus+) non-small cell lung cancer: a comprehensive genomic profiling study with histologic correlation
{{output}}
Background: Fusion of the RET gene resulting in clinically significant Genomic Alteration (GA) occur in 1-2% of NSCLC in the United States and has emerged as a major target for RET inhibitors which are first line treatment option... ...
